Abstract: Compounds of the formula (I) are disclosed which are Fab I inhibitors and are useful in the treatment of bacterial infections.

Abstract: The invention provides methods for identifying agonists and antagonists of FabK polypeptides.

Abstract: The present invention relates to a method for identifying protein—protein interactions. The interacting proteins are isolated by affinity chromatography and identified by mass spectrometry. The affinity chromatography method allows for the purification of unknown interacting proteins which are identified using mass spectrometric techniques. The invention provides a method for the high throughput analysis of protein—protein interactions that lends itself to automation.

Abstract: Compounds of the formula (I) are disclosed which are Fab I inhibitors and are useful in the treatment bacterial infections:

Abstract: Compounds of the formula (I) are disclosed which are FabI inhibitors and are useful in the treatment of bacterial infections.

Abstract: Prokayrotic FABI polypeptides and DNA (RNA) encoding such FABI and a procedure for such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such FABI for the treatment of infection, such as bacterial infections. Antagonists against such FABI and their use as a therapeutic to treat infections, such asstaphylococcal infections are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence of FABI nucleic acid sequences and the polypeptides in a host. Also disclosed are diagnostic assays for detecting polynucleotides encoding FABI and for detecting the polypeptide in a host.

Abstract: Compounds of formula (I) and (II) are disclosed wherein, R1, R2, R3, R4, X, A, B, D and Q are as disclosed in the specification, and the compounds are FabI inhibitors useful in the treatment of bacterial infections.

Abstract: Compounds of formula (I) and formula (II) are disclosed which are useful in the treatment bacterial infections: wherein: R1 is C1-4alkyl, Ar or 2-thienyl or 3-thienyl; R2 is C1-4alkyl or Ar; and n is 0-3; or a pharmaceutically acceptable salt thereof.

Abstract: A method and device to assist in the determination of protein domain boundaries is described. In particular the device is designed to provide a high throughput of proteolytic digestion of proteins to identify domains and their boundaries, for use in protein structure determination, in a manner that is amenable to automation. Proteases are immobilized in a convenient format such as a microtitre plate and preferably arranged in a matrix thereby allowing for simultaneous degradation of a protein by a number of proteases at a number of concentrations.

Abstract: Compounds of the formula (I) are disclosed which are FabI inhibitors and are useful in the treatment bacterial infections: wherein: R1 is Ar or Het; R2 is H, C1-6alkyl or Ar—C0-6alkyl; X is H, C1-4alkyl, OR′, SR′, C1-4alkylsulfonyl, C1-4alkylsulfoxyl, CN, N(R′)2, CH2N(R′)2, NO2, CF3, CO2R′, CON(R′)2, COR′, NR′C(O)R′, F, Cl, Br, I, or CF3S(O)r—; R′ is H, C1-6alkyl or Ar—C0-6alkyl; and r is 0, 1 or 2; or a pharmaceutically acceptable salt thereof.